000147846 001__ 147846
000147846 005__ 20250108101618.0
000147846 0247_ $$2doi$$a10.1183/23120541.00950-2020
000147846 0248_ $$2sideral$$a141362
000147846 037__ $$aART-2021-141362
000147846 041__ $$aeng
000147846 100__ $$aHalpin, David M.G.
000147846 245__ $$aINTREPID: single -versus multiple- inhaler triple therapy for COPD in usual clinical practice
000147846 260__ $$c2021
000147846 5060_ $$aAccess copy available to the general public$$fUnrestricted
000147846 5203_ $$aIntroductionReal-world trial data comparing single- with multiple-inhaler triple therapy (MITT) in COPD patients are currently lacking. The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and MITT were compared in usual clinical care.MethodsINTREPID was a multicentre, randomised, open-label, phase IV effectiveness study comparing FF/UMEC/VI 100/62.5/25 µgviathe ELLIPTA inhaler with a clinician's choice of any approved non-ELLIPTA MITT in usual COPD clinical practice in five European countries. Primary end-point was proportion of COPD Assessment Test (CAT) responders (≥2-unit decrease in CAT score from baseline) at week 24. Secondary end-points in a subpopulation included change from baseline in forced expiratory volume in 1 s (FEV1) and percentage of patients making at least one critical error in inhalation technique at week 24. Safety was also assessed.Results3092 patients were included (FF/UMEC/VI n=1545; MITT n=1547). The proportion of CAT responders at week 24 was significantly greater with FF/UMEC/VIversusnon-ELLIPTA MITT (OR 1.31, 95% CI 1.13–1.51; p<0.001) and mean change from baseline in FEV1was significantly greater with FF/UMEC/VI (77 mLversus28 mL; treatment difference 50 mL, 95% CI 26–73 mL; p<0.001). The percentage of patients with at least one critical error in inhalation technique was low in both groups (FF/UMEC/VI 6%; non-ELLIPTA MITT 3%). Safety profiles, including incidence of pneumonia serious adverse events, were similar between treatments.ConclusionsIn a usual clinical care setting, treatment with once-daily single-inhaler FF/UMEC/VI resulted in significantly more patients gaining health status improvement and greater lung function improvementversusnon-ELLIPTA MITT.
000147846 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000147846 590__ $$a4.239$$b2021
000147846 591__ $$aRESPIRATORY SYSTEM$$b29 / 66 = 0.439$$c2021$$dQ2$$eT2
000147846 592__ $$a0.944$$b2021
000147846 593__ $$aPulmonary and Respiratory Medicine$$c2021$$dQ2
000147846 594__ $$a4.6$$b2021
000147846 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000147846 700__ $$aWorsley, Sally
000147846 700__ $$aIsmaila, Afisi S.
000147846 700__ $$aBeeh, Kai-Michael
000147846 700__ $$aMidwinter, Dawn
000147846 700__ $$aKocks, Janwillem W.H.
000147846 700__ $$aIrving, Elaine
000147846 700__ $$0(orcid)0000-0001-9096-2294$$aMarin, José M.$$uUniversidad de Zaragoza
000147846 700__ $$aMartin, Neil
000147846 700__ $$aTabberer, Maggie
000147846 700__ $$aSnowise, Neil G.
000147846 700__ $$aCompton, Chris
000147846 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000147846 773__ $$g7, 2 (2021), 00950-2020$$pERJ open res.$$tERJ Open Research$$x2312-0541
000147846 8564_ $$s615994$$uhttps://zaguan.unizar.es/record/147846/files/texto_completo.pdf$$yVersión publicada
000147846 8564_ $$s2175537$$uhttps://zaguan.unizar.es/record/147846/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147846 909CO $$ooai:zaguan.unizar.es:147846$$particulos$$pdriver
000147846 951__ $$a2025-01-08-09:01:57
000147846 980__ $$aARTICLE